none of those compounds in ES3 are particularly orally bioavailable, likely less than 1%. The use of uncommon nomenclature to hide what the compounds actually are is also a reason IMO to avoid it. its 6-oxo, ATD, 3-ohat ether- its odd that you would need three aromatase inhibitors. even twice daily dosing with this compound will IMO lead to peaks and troughs in aromatase activity, if there is enough delivered to have effect (which is questionable).
this is the main reason that AIFM is a topical, also the time release factor inherent in topical delivery.